Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study-Reference-Cited by-同舟云学术

Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study

Published:2017-07-24 Issue: Volume:53 Page:2735-2757
ISSN:0017-9124
Container-title:Health Services Research
language:en
Short-container-title:Health Serv Res

Author:

Li Pengxiang¹²,Hu Tianyan³,Yu Xinyan⁴,Chahin Salim⁵,Dahodwala Nabila⁶,Blum Marissa⁷,Pettit Amy R.⁸,Doshi Jalpa A.⁹¹⁰¹^ORCID

Affiliation:

1. Leonard Davis Institute of Health Economics; University of Pennsylvania; Philadelphia PA

2. Department of Medicine; Perelman School of Medicine; University of Pennsylvania; Philadelphia PA

3. Department of Health Policy and Management; Robert Stempel College of Public Health & Social Work; Florida International University; Miami FL

4. QuintilesIMS Advanced Analytics; Philadelphia PA

5. Department of Neurology; Washington University in St. Louis; St. Louis MO

6. Parkinson's Disease and Movement Disorders Center; University of Pennsylvania; Philadelphia PA

7. Lewis Katz School of Medicine; Temple University; Philadelphia PA

8. Center for Public Health Initiatives; University of Pennsylvania; Philadelphia PA

9. Department of Medicine and Center for Evidence-based Practice; University of Pennsylvania; Philadelphia PA

10. Center for Health Incentives and Behavioral Economics; University of Pennsylvania; Philadelphia PA

Funder

Pfizer

Publisher

Wiley

Subject

Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1475-6773.12744/fullpdf

Reference62 articles.

1. Aitken , M. M. Kleinrock J. Lyle L. Caskey 2016 Medicines Use and Spending in the U.S.: A Review of 2015 and Outlook to 2020 http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020

2. Impact of Inadequate Adherence on Response to Subcutaneously Administered Anti-Tumour Necrosis Factor Drugs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort;Bluett;Rheumatology (Oxford, England),2015

3. Measurement and Rates of Persistence with and Adherence to Biologics for Rheumatoid Arthritis;Blum;Clinical Therapeutics,2011

4. Trends in RA Patients' Adherence to Subcutaneous Anti-TNF Therapies and Costs;Borah;Current Medical Research and Opinion,2009

5. Centers for Medicare and Medicaid Services 2014 Medicare Part D Specialty Tier https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/SpecialtyTierMethodology.pdf

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review;Multiple Sclerosis Journal;2023-09-12

2. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis;Exploratory Research in Clinical and Social Pharmacy;2023-09

3. Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review;International Journal of MS Care;2023-09-01

4. The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review;Journal of Managed Care & Specialty Pharmacy;2023-05

5. Giving A Buck Or Making A Buck? Donations By Pharmaceutical Manufacturers To Independent Patient Assistance Charities;Health Affairs;2022-09-01